Park, W., Kasi, A., Goldman, J. W., Pelster, M., Herzberg, B., Tolcher, A. W., Spira, A. I., Hollebecque, A., Shoji, H., Kuboki, Y., Wang, J. S., Berlin, J., Kadam, S., Lee, H., Gill, S., Saito, T., Poythress, J. C., Toyoshima, J., Fujii, H., Kitano, S. (2026). Phase 1 evaluation of ASP3082, a first-in-class selective protein degrader, in patients (pts) with
                    <i>KRAS G12D</i>
                    -mutant pancreatic ductal adenocarcinoma (PDAC): Pharmacokinetics (PK) and biomarker insights.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.2_suppl.775